Department of Radiation Oncology, Otto-von-Guericke University, Leipziger Str. 44, 39120, Magdeburg, Germany.
Department of Radiation Oncology, Helios Hospital Erfurt, Erfurt, Germany.
J Cancer Res Clin Oncol. 2023 Jul;149(8):5397-5404. doi: 10.1007/s00432-022-04491-3. Epub 2022 Nov 29.
A potential method for focal therapy in locally advanced prostate cancer is focal brachytherapy (F-BT). The purpose of this research was to evaluate midterm F-BT oncologic, functional, and toxicological results in men who had therapy for prostate cancer.
Between 2016 and 2020, F-BT was used to treat 37 patients with low- to intermediate-risk prostate cancer. The recommended dosage was 20 Gy. Failure was defined as the existence of any prostate cancer that has persisted in-field after treatment. The F-BT oncologic and functional outcomes served as the main and secondary objectives, respectively.
A median 20-month follow-up (range 14-48 months). 37 patients received F-BT and enrolled in the study; no patient experienced a biochemical recurrence in the first 24 months, according to Phoenix criteria. In the control biopsies, only 6 patients showed in-field failure. The median initial IPSS was 6.5, at 6 months was 6.0, and at 24 months was 5.0. When the median ICIQ-SF score was 0 at the baseline, it remained 0 at 6-, 12-, and 24 months. Overall survival and biochemical disease-free survival after 3 years were all at 100% and 86.4%, respectively. There was no notable acute gastro-intestinal (GI) or genitourinary (GU) adverse effects. No intraoperative or perioperative complications occurred.
For selected patients with low- or intermediate-risk localized prostate cancer, F-BT is a safe and effective therapy.
局部晚期前列腺癌的一种潜在的焦点治疗方法是焦点近距离放射治疗（F-BT）。本研究的目的是评估接受前列腺癌治疗的男性的 F-BT 肿瘤学、功能和毒理学的中期结果。
2016 年至 2020 年期间，F-BT 用于治疗 37 例低至中危前列腺癌患者。推荐剂量为 20Gy。失败定义为治疗后仍存在任何场内持续的前列腺癌。F-BT 的肿瘤学和功能结果分别作为主要和次要目标。
中位随访 20 个月（范围 14-48 个月）。37 例患者接受 F-BT 并纳入研究；根据凤凰标准，没有患者在 24 个月内出现生化复发。在对照活检中，只有 6 例患者显示场内失败。初始 IPSS 中位数为 6.5，6 个月时为 6.0，24 个月时为 5.0。当基线时 ICIQ-SF 评分中位数为 0 时，6、12 和 24 个月时仍为 0。3 年后的总生存率和生化无病生存率均为 100%和 86.4%。无明显急性胃肠（GI）或泌尿生殖系统（GU）不良事件。无术中或围手术期并发症。
对于选择的低危或中危局限性前列腺癌患者，F-BT 是一种安全有效的治疗方法。
